Date: 2014-01-06
Type of information: R&D agreement
Compound: antibodies based on the shark VNAR structure and bispecific biopharmaceuticals
Company: Lundbeck (Denmark) Ossianix (USA)
Therapeutic area: CNS diseases
Type agreement: R&D
Action mechanism:
Disease: pain
Details: * On January 6, 2014, Ossianix has announced a strategic research collaboration with Lundbeck. The collaboration uses Ossianix’s innovative single domain antibody platform based on the shark VNAR structure and will focus on two projects. The first project will further develop Ossianix’s VNAR antagonists targeting an ion channel for the treatment of pain. The second project utilizes Ossianix’s Blood Brain Barrier targeting technology for the development of bispecific biopharmaceuticals to treat CNS disorders. The Ossianix platform has the advantage of targeting antibodies to the CNS where existing antibodies have proven less than ideal due to poor bioavailability. Lundbeck will fund the research plan with development and regulatory milestones.
This collaboration follows a previous investment in 2012. On January 3, 2012, Ossianix has announced a strategic investment by Lundbeck in the form of a Convertible Promissory Note. The proceeds from Lundbeck’s investment was expected to allow Ossianix to generate biopharmaceuticals for the treatment of nervous system disorders by utilizing Ossianix’s proprietary single domain antibody platform modeled on the shark vNAR structure.
Financial terms:
Latest news:
